Oxytetracycline in the treatment of ocular rosacea: a double-blind trial.

AUTOR(ES)

Bartholomew, R S

RESUMO

Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continuous treatment 19/35 patients achieved a sustained remission for 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.

Documentos Relacionados

• Naproxen in osteoarthrosis. Double-blind crossover trial.
• Penotrane in blepharitis. A double-blind controlled trial.
• Fibrinolytic enhancement by stanozolol: a double-blind trial.
• Azathioprine in active chronic iridocyclitis. A double-blind controlled trial.
• Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial.